ここから本文です。

更新日:平成30(2018)年8月24日

臨床研究の主な成果

2017年3月現在

原著・総説・単行書・症例報告・その他

大規模な他施設共同試験の成果

 原著・総説・単行書・症例報告・その他

臨床試験推進部

1.   廣中秀一:第2章 胃がん ③セカンドラインの選択.1.     うまく続ける!消化器がん薬物療法の基本とコツ. 羊土社p60-68、2016(原著)

2.  廣中秀一:進行再発胃がんに対するがん化学療法のマネジメント 第2回「進行再発胃がんにおける二次化学療法の現状」.胃がんperspective 8(4):80-84, 2016(原著)

3.   廣中秀一:胃がんの分子標的治療-最近の動向.腫瘍内科 17(2):150-154, 2016(原著)

4.   廣中秀一:切除不能・再発胃がんの薬物療法アップデート -State-of-art-.Mebio 33(7):4-11, 2016(原著)

5.   廣中秀一:食道がん.医学のあゆみ がん標的分子と治療開発-現状と将来.258(5):518-522, 2016(原著)

6.   廣中秀一:エリアレビュー◎胃癌・座談会-最新エビデンスに基づく胃癌治療の在り方.日経メディカルOncologyレポート http://medical.nikkeibp.co.jp/leaf/mem/pub/search/cancer/report/201609/548233.html (Web 座談会)

7.  H.Bando, Y.Yamada, S.Tanabe, K.Nishikawa, M.Gotoh, N.Sugimoto, T.Nishina, K.Amagai, K.Chin, Y.Niwa, A.Tsuji, H.Imamura, M.Tsuda, H.Yasui, H.Fujii, K.Yamaguchi, H.Yasui, S.Hironaka, K.Shimada, H.Miwa, C.Hamada, I.Hyodo : Efficacy and safety of S-1 and oxaliplatin combination therapy in elderly patients with advanced gastric cancer. Gastric Cancer 19(3):919-926, 2016(原著)

8.  K.Shitara, K.Muro, Y.Shimada, S.Hironaka, N.Sugimoto, Y.Komatsu, T.Nishina, K.Yamaguchi, Y.Segawa, Y.Omuro, T.Tamura, T.Doi, S.Yukisawa, H.Yasui, F.Nagashima, M.Gotoh, T.Esaki, M.Emig, K.Chandrawansa, AM.Liepa, H.Wilke, Y.Ichimiya, A.Ohtsu : Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer. Gastric Cancer 19(3):927-938, 2016(原著)

9. C.Hamada, Y.Yamada, M.Azuma, K.Nishikawa, M.Gotoh, H.Bando, N.Sugimoto, T.Nishina, K.Amagai, K.Chin, Y.Niwa, A.Tsuji, H.Imamura, M.Tsuda, H.Yasui, H.Fujii, K.Yamaguchi, H.Yasui, S.Hironaka, K.Shimada, H.Miwa, I.Hyodo : Meta-analysis supporting noninferiority of oxaliplatin plus S-1 to cisplatin plus S-1 in first-line treatment of advanced gastric cancer (G-SOX study): indirect comparison with S-1 alone. Int J Clin Oncol 21(4):668-675, 2016(原著)

10.  T.Yokota, K.Kato, Y.Hamamoto, Y.Tsubosa, H.Ogawa, Y.Ito, H.Hara, T.Ura, T.Kojima, K.Chin, S.Hironaka, T.Kii, Y.Kojima, Y.Akutsu, H.Matsushita, K.Kawakami, K.Mori, Y.Nagai, C.Asami, Y.Kitagawa : Phase II study of chemoselection with docetaxel plus cisplatin and 5-fluorouracil induction chemotherapy and subsequent conversion surgery for locally advanced unresectable oesophageal cancer. Br J Cancer 115(11):1328-1334, 2016(原著)

11.  K.Nishikawa, Y.Yamada, K.Ishido, M.Gotoh, H.Bando, N.Sugimoto, T.Nishina, K.Amagai, K.Chin, Y.Niwa, A.Tsuji, H.Imamura, M.Tsuda, H.Yasui, H.Fujii, K.Yamaguchi, H.Yasui, S.Hironaka, K.Shimada, H.Miwa, C.Hamada, I.Hyodo : Impact of progression type on overall survival in patients with advanced gastric cancer based on randomized phase III study of S-1 plus oxaliplatin versus S-1 plus cisplatin. Gastric Cancer 2016 Nov 7. Epub 2016 Nov 7.(原著)

12.  廣中秀一:2次治療.考える胃癌化学療法.胃癌化学療法の要点と盲点.文光堂 p37-40、2017(原著)

13. K.Shitara, T.Doi, O.Nagano, CK.Imamura, T.Ozeki, Y.Ishii, K.Tsuchihashi, S.Takahashi, TE.Nakajima, S.Hironaka, M.Fukutani, H.Hasegawa, S.Nomura, A.Sato, Y.Einaga, T.Kuwata H.Saya, A.Ohtsu : Dose-escalation study for the targeting of CD44v+ cancer stem cells by sulfasalazine in patients with advanced gastric cancer (EPOC1205). Gastric Cancer 20(2):341-349, 2017(原著)

14. K.Kudo, Y.Hamamoto, K.Kato, T.Ura, T.Kojima, T.Tsushima, S.Hironaka, H.Hara, T.Satoh, S.Iwasa, K.Muro, H.Yasui, K.Minashi, K.Yamaguchi, A.Ohtsu, Y.Doki, Y.Kitagawa : Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicenter, phase 2 trial. Lancet Oncology Epub 2017 Mar 15.(原著)

15. T.Nishimura, M.Tamaoki, R.Komatsuzaki, N.Oue, H.Taniguchi, M.Komatsu, K.Aoyagi, K.Minashi, F.Chiwaki, H.Shinohara, Y.Tachimori, W.Yasui, M.Muto, T.Yoshida, Y.Sakai, H.Sasaki : SIX1 maintains tumor basal cells via transforming growth factor-β pathway and associates with poor prognosis in esophageal cancer. Cancer Sci 108(2):216-225, 2017(原著)

 

遺伝子診断部

1.   I.Hoshino, M.Nagata, N.Takiguchi, Y.Nabeya, A.Ikeda, S.Yokoi, A.Kuwajima, M.Tagawa, K.Matsushita, S.yajima, H.Shimada : A panel of autoantibodies against multiple tumor-associated antigens for detecting gastric cancer. Cancer Sci 108: 308-315, 2017.(原著)

2.  Y.Hasegawa, T.Iuchi, T.Sakaida, S.Yokoi, K.Kawasaki : The influence of carmustine wafer implantation on tumor bed cysts and peritumoral brain edema. J Clin Neurosci. 31:67-71, 2016..(原著)

食道・胃腸外科

1.   鍋谷圭宏、河津絢子、實方由美、前田恵理、掛巣孝則、高橋直樹:【がんの栄養管理と栄養指導エキスパートガイド】がん緩和医療の栄養管理 がん終末期の栄養サポート.臨床栄養 29(4):545-550, 2016(解説)

2.   鍋谷圭宏、永田松夫、星野敢、滝口伸浩、池田篤、外岡亨、早田浩明、有光秀仁、栁橋浩男、知花朝史、千葉聡、高山亘、前田佐知子、菅原武明:【周術期感染管理up-to-date】 上部消化管手術における感染管理.消化器外科 39(13):1761-1772, 2016(解説)

3.    鍋谷圭宏、今西俊介、坂本昭雄:【消化器手術のための栄養】術前栄養アセスメント.外科 78(8):799-804, 2016(解説)

4.   有光秀仁、鍋谷圭宏:【腸内細菌の今日的話題】腸内細菌を標的とした外科周術期感染管理.機能性食品と薬理栄養 10(1):433-436, 2016(解説)

5.    河津絢子、鍋谷圭宏、上野浩明、佐々木慶太:がん患者への栄養指導①頭頸部癌.臨床栄養 129(4):582-588, 2016(原著)

6.    鍋谷圭宏:実践臨床Q&A 第1章 アセスメント Q1. 癌治療における栄養指標とは?癌と臨床栄養(2版)、丸山道生編著、日本医事新報社、東京、pp152-154, 2016(分担執筆)

7.    鍋谷圭宏、永田松夫、河津絢子、掛巣孝則、前田恵理、上野浩明、實方由美、高橋直樹:食道癌周術期患者の栄養管理.栄養-Trends of Nutrition-1(1):39-41, 2016(原著)

8.    外岡亨、滝口伸浩、山本宏、鍋谷圭宏、池田篤、貝沼修、早田浩明、今西俊介、有光秀仁、小林亮介、知花朝史、石毛文隆、永田松夫:鼠径ヘルニア手術を契機に発見され腹腔鏡下に確定診断を得た虫垂粘液癌腹膜播種の1例 .癌と化学療法 43(12):2326-2328, 2016(原著)

9.    池田篤、滝口伸浩、鍋谷圭宏、外岡亨、貝沼修、山本宏、伊丹真紀子:腸間膜原発髄外性形質細胞腫の1例.日本消化器外科学会雑誌 49(8):746-753, 2016(原著)

10.  石毛文隆、貝沼修、山本宏、有光秀仁、栁橋浩男、今西俊介、小林亮介、知花朝史、滝口伸浩、鍋谷圭宏、:膵頭部と尾部に発生した多発分枝型膵管内乳頭粘液性腫瘍に対してmiddle-segment preserving pancreatectomyを施行した1例 .日本消化器外科学会雑誌 49(11): 1133-1140, 2016(原著)

11.  Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, Kaneoka Y, Shimizu Y, Nakamori S, Sakamoto H, Morinaga S, Kainuma O, Imai K, Sata N, Hishinuma S, Ojima H, Yamaguchi R, Hirano S, Sudo T, Ohashi Y; JASPAC 01 Study Group.: Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet 388:248-257, 2016(原著)

12.  I.Hoshino, M.Nagata, N,Takiguchi, A.Ikeda, S.Yokoi, A.Kuwajima, M.Tagawa, K.Matsushita, S.Yajima, H.Shimada: Panel of autoantibodies against multiple tumor-associated antigens for detecting gastric cancer. Cancer Sci 108(3):308-315, 2017(原著)

13.  今西俊介、貝沼修、鍋谷圭宏、小林亮介、知花朝史、石毛文隆:保存的に軽快した餅による食餌性腸閉塞の1例.日本腹部救急医学会雑誌 37(1):35-37, 2017(原著)

乳腺外科

1.  R.Nakamura, N.Yamamoto, N.Shiina,T.Miyaki, D.Ikebe, M.Itami, T.Shida, M Miyazaki : Impact of host and histopathological factors on the discrepancies in estrogen receptor, and progesterone receptor, and HER2 status between core needle biopsy and surgically excised tumors. Breast. 26: 141-147, 2016(原著)

2.  R.Nakamura and N.Yamamoto: Importance of breast imaging before and after RFA therapy. Non-surgical Ablation Therapy for Early-stage Breast Cancer. Kinoshita T, ed. Springer Japan, 2016, 9: 89-103(単行本、分担執筆)

3.  T.Aihara, T.Toyama, M.Takahashi, Y.Yamamoto, F.Hara, H.Akabane, T.Fujisawa, T.Ishikawa, S.Nagai, R.Nakamura, J.Tsurutani, Y.Ito, H.Mukai : The Japanese Breast Cancer Society Clinical Practice Guideline for systemic treatment of breast cancer, 2015 edition. Breast Cancer. 2016 May;23(3):329-42.(分担執筆)

4.  S.Akita, R.Nakamura, N.Yamamoto, H.Tokumoto, IT.shigaki, T.Yamaji, Y.Sasahara, Y.Kubota, N.Mitsukawa, K.Satoh: Early Detection of Lymphatic Disorder and Treatment for Lymphedema following Breast Cancer.. Plast Reconstr Surg. 2016 Aug;138(2):192e-202e(原著)

5.  K.Tamura, K.Inoue, N.Masuda, S.Takao, M.Kashiwaba, Y.Tokuda, H.Iwata, N.Yamamoto, K.Aogi, T.Saeki, T.Nakayama, N.Sato, T.Toyama, T.Ishida, H.Arioka, M.Saito, S.Ohno, H.Yamauchi, K.Yamada, J.Watanabe, H.Ishiguro, Y.Fujiwara: A randomized phase II study of nab-paclitaxel as first-line chemotherapy in patients with HER2-negative metastatic breast cancer. Cancer Sci. doi: 10.1111/cas.13221. [Epub ahead of print] 2017 Mar 3.(原著)(治験)

6.  S.Akita, R.Nakamura, N.Yamamoto, H.Tokumoto, IT.shigaki, T.Yamaji, Y.Sasahara,Y.Kubota, N.Mitsukawa, K.Satoh: Reply: Indocyanine Green Lymphography for Lymphedema Screening following Breast Cancer Treatment. Plast Reconstr Surg. 2017 Feb 14(原著)--有:形成外科

消化器内科

1. T.Denda, M.Kanda, Y.Morita, HM.Kim, T.Kashiwada, C.Matsuda, S.Fujieda, K.Nakata, K.Murotani, K.Oba, J.Sakamoto, H.Mishima: Pharmacokinetic dose adjustment of 5-FU in modified FOLFOX7 plus bevacizumab for metastatic colorectal cancer in Japanese patients: a-JUST phase II clinical trial. Cancer Chemother Pharmacol. 78(6):1253-1261, 2016(原著)

2.  E.Kita, T.Yamaguchi, K.Sudo: A case of needle tract seeding after EUS-guided FNA in pancreatic cancer, detected by serial positron emission tomography/CT. Gastrointest Endosc. 84(5):869-870, 2016(原著)

3.  高城秀幸、鈴木拓人、南金山理乃、稲垣千晶、今関洋、喜多絵美里、北川善康、須藤研太郎、中村和貴、原太郎、傳田忠道、瀬座勝志、山口武人:有茎性発育を呈した胃Hamartomatous inverted polypの2例.Progress of Digestive Endoscopy 88(1):90-91,4, 2016(原著)

4.  喜多絵美里、山口武人、菅原徳衛、高城秀幸、南金山理乃、今関洋、杉田統、辻本彰子、北川善康、須藤研太郎、鈴木拓人、中村和貴、傳田忠道、原太郎:【IPMNの診断と治療はどう変わったか?】 診断 ERCP、経口膵管鏡(POPS)による診断.胆と膵 37(11):1481-1487, 2016(解説)

5. 須藤研太郎:【消化器がん化学療法 Chemotherapy for Gastro-intestinal Cancer 2016】消化器がん化学療法の実際 消化器がんキードラッグの基礎知識 ゲムシタビン. 臨床消化器内科  31(7):881-887, 2016(解説)

6.  新井裕之、廣中秀一:【消化器がん化学療法 Chemotherapy for Gastro-intestinal Cancer 2016】消化器がん化学療法の実際 消化器がんキードラッグの基礎知識 キナーゼ阻害薬 イマチニブ、ソラフェニブ、スニチニブ、レゴラフェニブ.臨床消化器内科 31(7): 894-898, 2016(解説)

7.  須藤研太郎、中村和貴、今関洋、喜多絵美里、辻本彰子、山口武人:【膵・胆道癌の治療戦略:こんなときどうするか?-ガイドラインにないエキスパートオピニオン-】 ゲムシタビン+ナブパクリタキセル療法耐性後の治療選択. 胆と膵 37(6):531-534, 2016(解説)

8. 今関洋、須藤研太郎、菅原徳衛、高城秀幸、南金山理乃、杉田統、辻本彰子、喜多絵美里、中村和貴、傳田忠道、高山亘、山口武人:【膵癌血管浸潤例の外科切除適応と治療ストラテジー:Up to date 2016】 膵癌血管浸潤の診断と外科切除の適応 術前画像診断からわかる膵癌血管浸潤の診断能と限界.胆と膵 37(7):607-612, 2016(解説)

9.  高城秀幸、鈴木拓人、南金山理乃、稲垣千晶、今関洋、喜多絵美里、北川善康、須藤研太郎、中村和貴、原太郎、傳田忠道、瀬座勝志、山口武人:有茎性発育を呈した胃Hamartomatous inverted polypの2例.Progress of Digestive Endoscopy (1348-9844)88巻1号 Page90-91,4 2016(原著)

10.  辻本彰子、須藤研太郎、中村和貴、今関洋、喜多絵美里、高山亘、山口武人:【胆膵内視鏡自由自在~基本手技を学び応用力をつける集中講座~】 ERCP関連手技編 胆道ドレナージ術 Bridge to Surgery 遠位胆道閉塞.胆と膵 37巻臨増特大 Page1269-1272, 2016(解説)

11. K.Yamazaki, M.Nagase, H.Tamagawa, S.Ueda, T.Tamura, K.Murata, T.Eguchi Nakajima, E.Baba, M.Tsuda, T.Moriwaki, T.Esaki, Y.Tsuji, K.Muro, K.Taira, T.Denda, S.Funai, K.Shinozaki, H.Yamashita, N.Sugimoto, T.Okuno, T.Nishina, M.Umeki, T.Kurimoto, T.Takayama, A.Tsuji, M.Yoshida, A.Hosokawa, Y.Shibata, K.Suyama, M.Okabe, K.Suzuki, N.Seki, K.Kawakami, M.Sato, K.Fujikawa, T.Hirashima, T.Shimura, K.Taku, T.Otsuji, F.Tamura, E.Shinozaki, K.Nakashima, H.Hara, T.Tsushima, M.Ando, S.Morita, N.Boku, I.Hyodo.: Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G). Ann Oncol. 27(8):1539-1546, 2016(原著)

12. Y.Sunakawa, D.Yang, M.Moran, SH.Astrow, A.Tsuji, C.Stephens, W.Zhang, S.Cao, T.Takahashi, T.Denda, K.Shimada, M.Kochi, M.Nakamura, M.Kotaka, Y.Segawa, T.Masuishi, M.Takeuchi, M.Fujii, T.Nakajima, W.Ichikawa, HJ.Lenz: Combined assessment of EGFR-related molecules to predict outcome of 1st-line cetuximab-containing chemotherapy for metastatic colorectal cancer. Cancer Biol Ther. 17(7):751-759, 2016(原著)

13. K.Shitara, K.Yonesaka, T.Denda, K.Yamazaki, T.Moriwaki, M.Tsuda, T.Takano, H.Okuda, T.Nishina, K.Sakai, K.Nishio, S.Tokunaga, T.Yamanaka, N.Boku, I.Hyodo, K.Muro: Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild-type KRAS colorectal cancer-WJOG 6210G. Cancer Sci. 107(12):1843-1850, 2016(原著)

14. T.Nishina, T.Moriwaki, M.Shimada, J.Higashijima, Y.Sakai, T.Masuishi, M.Ozeki, K.Amagai, Y.Negoro, A.Indo, T.Denda, M.Sato, Y.Yamamoto, G.Nakajima, M.Mizuta, I.Takahashi, Y.Hiroshima, H.Ishida, T.Maeba, I.Hyodo: Uracil-Tegafur and Oral Leucovorin Combined With Bevacizumab in Elderly Patients (Aged ≥ 75 Years) With Metastatic Colorectal Cancer: A Multicenter, Phase II Trial (Joint Study of Bevacizumab, Oral Leucovorin, and Uracil-Tegafur in Elderly Patients [J-BLUE] Study). Clin Colorectal Cancer. 15(3):236-242, 2016(原著)

15. Y.Sunakawa, W.Ichikawa, A.Tsuji, T.Denda, Y.Segawa, Y.Negoro, K.Shimada, M.Kochi, M.Nakamura, M.Kotaka, H.Tanioka, A.Takagane, S.Tani, T.Yamaguchi, T.Watanabe, M.Takeuchi, M.Fujii, T.Nakajima: Prognostic Impact of Primary Tumor Location on Clinical Outcomes of Metastatic Colorectal Cancer Treated With Cetuximab Plus Oxaliplatin-Based Chemotherapy: A Subgroup Analysis of the JACCRO CC-05/06 Trials. Clin Colorectal Cancer. 2017 Sep;16(3):e171-e180. doi: 10.1016/j.clcc.2016.09.010. Epub 2016 Oct 6., 2016(原著)

16. S.Nakaji, S.Nakaji, N.Hirata, R.Mikata, M.Kobayashi, T.Shiratori, S.Ogasawara, Y.Ooka, T.Tsuyuguchi, T.Yamaguchi, O.Yokosuka: Clinical outcomes of endoscopic ultrasound-guided ethanol injection for hepatocellular carcinoma in the caudate lobe. Endosc Int Open. 4(10):E1111-E1115, 2016(原著)

17.  T.Nishi, Y.Hamamoto, M.Nagase, T.Denda, K.Yamaguchi, K.Amagai, Y.Miyata, Y.Yamanaka, K.Yanai, T.Ishikawa, Y.Kuroki, H.Fujii: Phase II trial of panitumumab with irinotecan as salvage therapy for patients with advanced or recurrent colorectal cancer (TOPIC study). Oncol Lett. 11(6):4049-4054, 2016(原著)

18. A.Tsuji, A.Tsuji, Y.Sunakawa, W.Ichikawa, M.Nakamura, M.Kochi, T.Denda, T.Yamaguchi, K.Shimada, A.Takagane, S.Tani, M.Kotaka, H.Kuramochi, K.Furushima, J.Koike, Y.Yonemura, M.Takeuchi, M.Fujii, T.Nakajima: Early Tumor Shrinkage and Depth of Response as Predictors of Favorable Treatment Outcomes in Patients with Metastatic Colorectal Cancer Treated with FOLFOX Plus Cetuximab (JACCRO CC-05). Target Oncol. 1(6):799-806, 2016(原著)

19. T.Ioka, Y.Komatsu, N.Mizuno, A.Tsuji, S.Ohkawa, M.Tanaka, H.Iguchi, A.Ishiguro, M.Kitano, T.Satoh, T.Yamaguchi, K.Takeda, M.Kida, K.Eguchi, T.Ito, M.Munakata, T.Itoi, J.Furuse, C.Hamada, Y.Sakata: Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancer. Br J Cancer. 116(4):464-471, 2017(原著)

内視鏡科

1.  T.Suzuki, T.Hara, Y.Kitagawa, T.Yamaguchi : Magnified endoscopic observation of early colorectal cancer by linked color imaging with crystal violet staining (with video). Gastrointest Endosc. 84(4):726-729, 2016(原著)

2. Y.Kitagawa, D.Ikebe, T.Hara, K.Kato, T.Komatsu, F.Kondo, R.Azemoto, F.Komoda, T.Tanaka, H.Saito, M.Itami, T.Yamaguchi, T.Suzuki: Enhanced detection of lymphovascular invasion in small rectal neuroendocrine tumors using D2-40 and Elastica van Gieson immunohistochemical analysis. Cancer Med. 5(11):3121-3127,2016(原著)(26-66)

3. Y.Kitagawa, D.Ikebe, T.Suzuki, T.Hara, M.Itami, T.Yamaguchi: Frequent Presence of Lymphovascular Invasion in Small Rectal Neuroendocrine Tumors on Immunohistochemical Analysis. Digestion. 95(1):16-21,2017(原著)(26-66)

4.  T.Suzuki, T.Hara, Y.Kitagawa, H.Takashiro, R.Nankinzan, O.Sugita, T.Yamaguchi: Linked-color imaging improves endoscopic visibility of colorectal nongranular flat lesions. Gastrointest Endosc. pii: S0016-5107(17)30088-3,2017 Feb 11, 2017(原著)(迅28-30)

呼吸器外科

1.  石橋史博、椎名裕樹、松井由紀子、守屋康充、飯笹俊彦:高齢男性に発症し孤立性肋骨転移をきたした縦隔原発混合性胚細胞腫瘍の1例.肺癌 56:27-32, 2016(症例報告)

2.   吉田成利:胸腔ドレーンの管理.日本呼吸器外科学会・呼吸器外科専門医合同委員会 編集. 呼吸器外科テキスト-外科専門医・呼吸器外科専門医をめざす人のために.南江堂. pp65-68, 2016(分担執筆)

3.  H.Ashinuma, M.Shingyoji, Y.Yoshida, M.Itakura, T.Iizasa, Y.Sakashita, I.Sekine: Retrospective analysis of lung cancer patients treated with supportive care alone. Int J Clin Oncol 2017 Jan 31, doi:10.1007/s10147-017-1094-1. [Epub ahead of prit](原著)

4. T.Murakawa, H.Sato, S.Okumura, J.Nakajima, Y.Ozeki, H.Asamura, N.Ikeda, H.Otsuka, H.Matsuguma, I.Yoshino, M.Chida, M.Nakayama, T.Iizasa, M.Okumura, S.Shiono, R.Kato, T.Iida, N.Matsutani, M.Kawamura, Y.Sakao, K.Funai, G.Furuyashiki, H.Akiyama, S.Sugiyama, N.Kanauchi, Y.Shiraishi; Metastaic Lung Tumor Study Group pf Japan: Thoracoscopic surgery versus open surgery for lung metastases of colorectal cancer: a multi-institutional retrospective analysis using propensity score adjustment. Eur J Cardiothorac Surg 2017.Feb 16. Doi: 10.1093/ejcts/ezx020. [Epub ahead of prit]2017(原著)

呼吸器内科

1.  Y.Jiang, B.Zhong, K.Kawamura, T.Morinaga, M.Shingyoji, I.Sekine, Y.Tada, K.Tatsumi, H.Shimada, K.Hiroshima, M.Tagawa: Combination of a third generation bisphosphonate and replication-competent adenoviruses augments the cytotoxicity on mesothelioma. BMC Cancer. 2016 Jul 12;16(1):455, 2016(原著)

2.  H.Ashinuma, M.Shingyoji, Y.Yoshida, M.Itakura, T.Iizasa, Y.Sakashita, I.Sekine: Retrospective analysis of lung cancer patients treated with supportive care alone. Int J Clin Oncol. 2017 Jan 31., 2017(原著)(迅26-77)

腫瘍・血液内科

1.  M.Ise, K.Matsubayashi, H.Tsujimura, K.Kumagai: Loss of CD38 Expression in Relapsed Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma & Leukemia, Vol. 16, No. 5, e59-64 2016(症例報告)

2. 佐藤昌靖、辻村秀樹、杉山孝弘、丸山聡、山田修平、小野敬子、王暁斐、菅原武明、伊勢美樹子、伊丹真紀子、熊谷匡也:大量出血を来した3例の小腸原発濾胞性リンパ腫. 臨床血液 57(3), 353-358, 2016(症例報告)

外来化学療法科

1.  M.Ise, K.Matsubayashi, H.Tsujimura, K.Kumagai: Loss of CD38 Expression in Relapsed Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma & Leukemia, Vol. 16, No. 5, e59-64 2016(症例報告)

2.  佐藤昌靖、辻村秀樹、杉山孝弘、丸山聡、山田修平、小野敬子、王暁斐、菅原武明、伊勢美樹子、伊丹真紀子、熊谷匡也:大量出血を来した3例の小腸原発濾胞性リンパ腫. 臨床血液 57(3): 353-358, 2016(症例報告)

3.  小野敬子、伊勢美樹子、池部大、佐藤昌靖、王暁斐、菅原武明、辻村秀樹、伊丹真紀子、熊谷匡也: Biweekly CHOP療法が奏効した骨髄浸潤を伴う再発芽球性形質細胞様樹状細胞腫瘍. 臨床血液 58 (2): 150-154, 2017(症例報告)

4. 辻村秀樹:高齢者マントル細胞リンパ腫の治療. EBM 血液疾患の治療(金倉譲 編集) 中外医学社, 244-249, 2017(分担執筆)

5. 辻村秀樹:抗がん薬治療と感染症. がんの治療と暮らしのサポート実践ガイド NPO法人キャンサーリボンズ: p120-125, 2017(総説)

脳神経外科

1.  .Hasegawa, T.Iuchi, T.Sakaida, S.Yokoi, K.Kawasaki : The influence of carmustine wafer implantation on tumor bed cysts and peritumoral brain edema. J Clin Neurosci. 31:67-71, 2016..(原著)

2.  井内俊彦:-脳腫瘍の治療 脳腫瘍の放射療法IMRT/VMAT.日本臨床74巻増刊7「脳腫瘍学-基礎研究と臨床研究の進歩-」.577-582, 2016(解説)

3. K.Ichimura, T.Iuchi, et.al.: Recurrent neomorphic mutations of MTOR in central nervous system and testicular germ cell tumors may be targeted for therapy. Acta Neuropathol. 131(6):889-901, 2016(原著)

4.  M.Furuse, T.Iuchi, et.al.: A prospective, multicentre, single-arm clinical trial of bevacizumab for patients with surgically untreatable, symptomatic brain radiation necrosis†. Neurooncol Pract. 3(4):272-280, 2016(原著)

5.  T.Wawkabayashi, T.Iuchi, et.al.: Diagnostic Performance and Safety of Positron Emission Tomography Using 18F-Fluciclovine in Patients with Clinically Suspected High- or Low-grade Gliomas: A Multicenter Phase IIb Trial. Asia Ocean J Nucl Med Biol. 2017 Winter;5(1):10-21, 2017(原著)

6.  S.Fukushima, T.Iuchi, et.al.: Genome-wide methylation profiles in primary intracranial germ cell tumors indicate a primordial germ cell origin for germinomas. Acta Neuropathol. 133(3):445-462, 2017(原著)

頭頸科

1.  T.Suzuki, T.Sakurai, et.al.: Characteristics of laryngeal symptoms induced in patients with allergic rhinitis in an environmental challenge chamber. Ann Allergy Asthma Immunol. 116(6):491-496, 2016(原著)

2.  Y.Okuma, T.Sakurai, et.al.: Persistent nasal symptoms and mediator release after continuous pollen exposure in an environmental challenge chamber. Ann Allergy Asthma Immunol.117(2):150-157, 2016(原著)

婦人科

1.  Y.Maru, N.Tanaka, M.Ohira, M.Itami, Y.Hippo, H.Nagase: Identification of novel mutations in Japanise ovarian clear cell carcinoma patients using optimized targeted NGS for clinical diagnosis. Gynectol Oncol 144(2):377-383, 2017(原著)

泌尿器科

1.  植田健、小丸淳、梨井隼菱、小林将行、深沢賢:前立腺癌の分子生物学と発癌機序 前立腺癌の分子生物学・遺伝学 前立腺癌の癌遺伝子・癌抑制遺伝子. 日本臨床 74巻増刊3 「新前立腺癌学-最新の基礎研究と診断・治療」: 60-64, 2016(解説)

2.  H.Akaza, S.Fukasawa, et.al.: A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer. Int J Clin Oncol. 21(4):773-782, 2016(原著)

3.  B.Escudier, T.Ueda, et.al.: CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma. Eur Urol. 2017 Mar 3. pii: S0302-2838(17)30099-4. doi: 10.1016/j.eururo.2017.02.010. [Epub ahead of print]

4.   H.Suzuki, S.Fukasawa, et.al.: Diagnostic performance and safety of NMK36 (trans-1-amino-3-[18F] fluorocyclobutanecarboxylic acid)-PET/CT in primary prostate pancer: multicenter Phase IIb clinical trial. Jpn J Clin Oncol. 47(3):283, 2017(原著)

5.  G.Kkimura, T.Ueda, et.al.: Enzalutamide in Japanese patients with chemotherapy-naïve, metastatic castration-resistant prostate cancer: A post-hoc analysis of the placebo-controlled PREVAIL trial. Int J Urol. 23(5):395-403, 2016(原著)

6.  Y.Tomita, S.Fukasawa, et.al.: Key predictive factors for efficacy of axitinib in first-line metastatic renal cell carcinoma: subgroup analysis in Japanese patients from a randomized, double-blind phase II study. Jpn J Clin Oncol. 2016 Aug 29. [Epub ahead of print], 2016(原著)

7. BI.Rini, T.Ueda, et.al.: Overall Survival Analysis From a Randomized Phase II Study of Axitinib With or Without Dose Titration in First-Line Metastatic Renal Cell Carcinoma. Clin Genitourin Cancer. 14(6):499-503, 2016(原著)

8. G.Kkimura, T.Ueda, et.al.: Post hoc analysis of Japanese patients from the placebo-controlled PREVAIL trial of enzalutamide in patients with chemotherapy-naive, metastatic castration-resistant prostate cancer-updated results. Jpn J Clin Oncol. 47(3):262-264, 2017(原著)

9. K.Tatsugami, S.Fukasawa, et.al.: Reality of nerve sparing and surgical margins in surgeons' early experience with robot-assisted radical prostatectomy in Japan. Int J Urol.24(3):191-196, 2017(原著)

10. M.Ku, T.Ueda, et.al.: Up-Regulation of LAT1 during Antiandrogen Therapy Contributes to Progression in Prostate Cancer Cells. J Urol.195(5):1588-1597, 2016(原著)

11. 佐藤陽介, 竹下 暢重, 篠崎 哲男, 梨井 隼菱, 小林 将行, 本間之夫, 市川 智彦, 植田 健, 小丸 淳, 深沢 賢

腹部手術歴のある症例に対するロボット支援腹腔鏡下前立腺全摘術の検討Japanese Journal of Endourology 2016 29(2) :220-223

整形外科

1. T.Yonemoto, M.Takahashi, M.Maru, A.Tomioka, M.Saito, Y.Araki, M.Tazaki, M.Tsuchiya, S.Iwata, H.Kamoda, T.Ishii:Marriage and fertility in long-term survivors of childhood, adolescent and young adult (AYA) high-grade sarcoma. Int J Clin Oncol 2016 Aug; 21(4): 801-807.(原著)(26-46)

2. 米本司:小児骨肉腫患者における成人期移行の現状と問題点..小児科臨床 2016; 69(4): 561-565.特集(依頼原稿)

3.  S.Okimatsu, H.Kamoda, T.Yonemoto, S.Iwata, T.Ishii: Effectiveness of Clavicula Pro Humero Reconstruction for Elderly Patients: Report of Two Cases. Case Rep Oncol Med. 2016; Epub 2016 Oct 25, 2016(原著)

4.  D.Kajiwara, H.Kamoda, T.Yonemoto, S.Iwata, T.Ishii, T.Tsukanishi, S.Ohtori, M.Yamazaki, A.Okawa: Denosumab for Treatment of a Recurrent Cervical Giant-Cell Tumor. Asian Spine J. 10(3):553-557, 2016(原著)

5.  S.Iwata, K.Uehara, K.Ogura, T.Akiyama, Y.Shinoda, T.Yonemoto, A.Kawai: Reliability and Validity of a Japanese-language and Culturally Adapted Version of the Musculoskeletal Tumor Society Scoring System for the Lower Extremity. Clin Orthop Relat Res. 2016 Sep;474(9):2044-2052.(原著)

6.  H.Morioka, S.Takahashi, N.Araki, H.Sugiura, T.Ueda, M.Takahashi, T.Yonemoto, H.Hiraga, T.Hiruma, T.Kunisada, A.Matsumine, M.Susa, R.Nakayama, K.Nishimoto, K.Kikuta, K.Horiuchi, A.Kawai: Results of sub-analysis of a phase 2 study on trabectedin treatment for extraskeletal myxoid chondrosarcoma and mesenchymal chondrosarcoma. BMC Cancer 2016 Jul; 16: 479.(原著)(治験10045030)

7.  秋山逹、上原浩介、小倉浩一、税田和夫、岩田慎太郎、米本司、石井猛、篠田裕介、河野博隆、櫻井卓郎、中馬広一、川井章:日本語版Toronto Extremity Salvage Score (TESS)-上肢の開発: 言語的妥当性を担保した翻訳版の作成.整形外科 67(9): 933-937, 2016(原著)(26-39)

8.  T.Nakamura, CL.Gaston, K.Reddy, S.Iwata, J.Nishio: Inflammatory Biomarkers in Cancer. Mediators Inflamm. 2016; Epub 2016 Oct 23, 2016(分担執筆)

9.   RA.Toledo, Y.Qin, ZM.Cheng, Q.Gao, S.Iwata, GM.Silva, ML.Prasad , IT.Ocal, S.Rao, N.Aronin, M.Barontini, J.Bruder, RL.Reddick, Y.Chen, RC.Aguiar, OL.Dahia: Recurrent Mutations of Chromatin-Remodeling Genes and Kinase Receptors in Pheochromocytomas and Paragangliomas. Clin Cancer Res. 22(9):2301-2310, 2016(原著)

10.  岩田慎太郎:原発生悪性骨腫瘍(骨肉腫、他).今日の治療指針 2017年版(総説)

11.  T.Akiyama, K.Uehara, K.Ogura, Y.Shinoda, S.Iwata, K.Saita, Y.Tanzawa, F.Nakatani, T.Yonemoto, H.Kawano, AM.Davis, A.Kawai: Cross-cultural adaptation and validation of the Japanese version of the Toronto Extremity Salvage Score (TESS) for patients with malignant musculoskeletal tumors in the upper extremities. J Orthop Sci. 22(1):127-132, 2017(原著)

緩和医療科

1.  坂下美彦、藤川文子、秋月晶子、藤里正視:抗がん治療を受ける患者の大切に思う領域と主観的QOL ―緩和ケア外来でのSEIQoL-DW横断的評価-.Palliative Care Reserch(日本緩和医療学会誌) 11(2):182-188, 2016(原著)(26-24)

2.  坂下美彦:地域包括ケア時代の緩和ケアネットワーク体制の整備(がん患者が安心して過ごせるように).看護管理 26(2):130-135, 2016(総説)

3.  坂下美彦:在宅緩和ケアにおけるがん診療連携拠点病院の役割 . 特集 在宅緩和ケアの現状と課題.Progress in Medicine. 36(10): 67-70, 2016(総説)

4.  坂下美彦:特集 緩和ケアの魔法の言葉.1.頑張る患者・家族への魔法の言葉緩「あなたに金メダルをあげたい」.緩和ケア. 26(6月増刊).20-22, 2016(その他)

5.  坂下美彦:特集 緩和ケアの魔法の言葉.6.在宅や緩和ケア病棟を紹介する時の魔法の言葉緩「とてもいい先生ですよ」.緩和ケア. 26(6月増刊).130-132, 2016(その他)

6.  R.Nagashima,M.Aoyagi,M.Fujisato:The potential therapeutic power of music for cancer patients.Music Therapy Today WFMT Online Journal 13(1): 468-469、2016(原著)

精神腫瘍科

1.   秋月伸哉:【泌尿器科処方のすべて-すぐに使える実践ガイド】 腫瘍 緩和医療 がん患者の精神症状・せん妄.臨床泌尿器科 70(4): 230-234, 2016(解説)

2.  秋月伸哉:【泌尿器科処方のすべて-すぐに使える実践ガイド】 周術期 ハイリスク患者の管理 精神疾患を伴う患者.臨床泌尿器科 70(4): 272-275, 2016(解説)

3.  秋月伸哉:【泌尿器科処方のすべて-すぐに使える実践ガイド】 周術期 術後愁訴と合併症 せん妄.臨床泌尿器科 70(4): 280-282, 2016(解説)

4.  A.Igarashi, N.Akizuki, et.al.: Association Between Bereaved Families' Sense of Security and Their Experience of Death in Cancer Patients: Cross-Sectional Population-Based Study. J Pain Symptom Manage. 51(5):926-932, 2016(原著)

放射線治療部

1.   河内徹、片寄哲朗、宮阪遼平、曺翔永、清水孝行、笹川竜、平岡卓也、中井圭介、石川真也、秦和也、山下慶、岩瀬勉:水吸収線量計測における不確かさ.日本放射線技術学会雑誌 72(8):701-707, 2016(原著)

2.  片寄哲朗、河内徹、宮阪遼平、兒玉匠、高瀬信宏、入山絵梨、張維珊、齋藤秀敏: Flattening Filter Freeビームにおける水吸収線量計測に関する提案 .医学物理 36(2):79-84, 2016(原著)

臨床検査部

1.   滝口伸浩、鍋谷圭宏、島崎怜理、池田篤、早田浩明、外岡亨、貝沼修、今西俊介、有光秀仁、小林亮介、知花朝史、石毛文隆、山本宏、永田松夫、鈴木拓人: 85歳以上胃癌症例に対する外科的、内視鏡的治療の現況.癌と化学療法 43(12): 1508-151, 2016(原著)

2.  K.Koda, H.Miyauchi, C.Kosugi, T.Kaiho, N.Takiguchi, S.Kobayashi, T.Maruyama, H.Matsubara: Tumor 5-FU-related mRNA Expression and Efficacy of Oral Fluoropyrimidines in Adjuvant Chemotherapy of Colorectal Cancer. Anticancer Res. 36(10):5325-5331, 2016(原著)

3.  H.Maeda, M.Sato, M.Kobayashi, N.Takiguchi, T.Yoshikawa, S.Yoshino, K.Yoshida, A.Tsuburaya, J.Sakamoto, S.Morita: Validity of the Japanese version of functional assessment of cancer therapy-gastric (FACT-Ga) and its sensitivity to ascites volume change: a retrospective analysis of Japanese clinical trial participants. Support Care Cancer. 24(11):4515-4521, 2016(原著)

4.  S.Fujita, J.Mizusawa, Y.Kanemitsu, M.Ito, Y.Kinugasa, K.Komori, M.Ohue, M.Ota, Y.Akazai, M.Shiozawa, T.Yamaguchi, H.Bandou, K.Katsumata, K.Murata, Y.Akagi, N.Takiguchi, Y.Saida, K.Nakamura, H.Fukuda, T.Akasu, Y.Moriya: Mesorectal Excision With or Without Lateral Lymph Node Dissection for Clinical Stage II/III Lower Rectal Cancer (JCOG0212): A Multicenter, Randomized Controlled, Noninferiority Trial. Ann Surg. 2017 Mar 10. [Epub ahead of print](原著)

5.  S.Ida, N.Hiki, H.Cho, K.Sakamaki, S.Ito, K.Fujitani, N.Takiguchi, Y.Kawashima, K.Nishikawa, M.Sasako, T.Aoyama, M.Honda, T.Sato, S.Nunobe, T.Yoshikawa: Randomized clinical trial comparing standard diet with perioperative oral immunonutrition in total gastrectomy for gastric cancer. Br J Surg. 104(4):377-383, 2017(原著)

6.  Y.Kodera, N.Takahashi, T.Yoshikawa, N.Takiguchi, K.Fujitani, Y.Ito, K.Miyamoto, O.Takayama, M.Imano, D.Kobayashi, Y.Miyashita, D.Morita, J.Sakamoto: Feasibility of weekly intraperitoneal versus intravenous paclitaxel therapy delivered from the day of radical surgery for gastric cancer: a preliminary safety analysis of the INPACT study, a randomized controlled trial. Gastric Cancer. 20(1):190-199, 2017(原著)

臨床病理部

1.  Y.Kitagawa, D.Ikebe, T.hara, K.Kato, T.Komatsu, F.Kondo, R.Azemoto, F.Komoda, T.Tanaka, H.Saito, M.Itami, T.Yamaguchi & T.Suzuki: Enhanced detection of lymphovascular invasion in small rectal neuroendocrine tumors using D2-40 and Elastic van Gieson immunohistochemical analysis. Cancer Med 5(11): 3121–3127, 2016(原著)

2.  R.Nakamura, N.Yamamoto, N.Shiina,T.Miyaki, D.Ikebe, M.Itami, T.Shida, M Miyazaki : Impact of host and histopathological factors on the discrepancies in estrogen receptor, and progesterone receptor, and HER2 status between core needle biopsy and surgically excised tumors. Breast. 26: 141-147, 2016(原著)

3.  K.Kawamura, A.Wada, J-Y.Wang, Q.Li, A.Ishii, H.Tsujimura, T.Takagi, M.Itami, Y.Tada, K.Tatsumi, H.Shimada, K.Hiroshima, M.Tagawa: Expression of activation-induced cytidine deaminase is associated with a poor prognosis of diffuse B cell lymphoma patients treated with CHOP-based chemotherapy. Cancer Res Clin Oncol 142:27-36(2016)(原著)

栄養科

1.  河津絢子、鍋谷圭宏、上野浩明、佐々木慶太:がん患者への栄養指導①頭頸部癌 .臨床栄養 129(4):582-588, 2016(原著)

看護局

1.   新川智子:上司と相談しながら段階的に復帰、経験を看護に活かす方法を模索中.看護 68(13): 77-78, 2016(総説)

2.    山田みつぎ:他施設の工夫に学ぶ曝露対策 「これだけは知っておこう!曝露対策の基礎知識」. Oncology Nurse 9(5): 3-11, 2016(総説)

3.   山田みつぎ:消化器がん化学療法で行われるレジメンと治療中のケアの疑問解決 「Q:食道がんで行われるFP療法、NDP+5FU療法、DTX療法やFP+RT療法のポイントと留意点を教えてください」.消化器最新看護 21(4): 6-12, 2016(総説)

4.  松原裕理、山田みつぎ:緩和ケアにおける「口の症状」への対応 「化学療法/放射線療法が始まる前にできることと、発生後のケア」緩和ケア 27(1): 13-19, 2017(総説)

5.   山田みつぎ:セルフマネジメントを支える. がんの治療と暮らしのサポート実践ガイド NPO法人キャンサーリボンズ: p21-28, 2017(総説)

6.   山田みつぎ:吐き気のマネジメント. がんの治療と暮らしのサポート実践ガイド NPO法人キャンサーリボンズ: p135-142, 2017(総説)

7.  山田みつぎ: QOLを支える口腔ケア. がんの治療と暮らしのサポート実践ガイド NPO法人キャンサーリボンズ: p143-158, 2017(総説)

研究所

1.  J.Lin, K.Hiraoka, T.Watanabe, T.Kuo, Y.Shinozaki, A.Takatori, N.Koshikawa, A.Chandran, J.Otsuki, H.Sugiyama, P. Horto, H. Nagase:Identification of Binding Targets of a Pyrrole-Imidazole Polyamide KR12 in the LS180 Colorectal Cancer Genome. PLoS ONE 11(10): e0165581, 2016..(原著)

2.  T.Watanabe, K.Shinohara, Y.Shinozaki, S.Uekusa, X.Wang, N.Koshikawa, K.Hiraoka, T.Inoue, J.Lin, T.Bando, H.Sugiyama, H.Nagase:Double beta-alanine substitutions incorporated in 12-ring pyrrole-Imidazole Polyamides for lengthened DNA minor groove recognition. Adv. Tech. Biol. Med. 4(2), 2016..(原著)--無--無

3.  中村洋子、高山喜美子、稲田潤子、横畑由紀子、横山よし子、高峰友紀子、江口高子、船戸静子、髙橋志保子、三上春夫、永瀬浩喜:千葉県がん登録から全国がん登録へ.JACR Monograph No.22, p84, 2016(その他)

4.   S.Satoh, A.Takatori, A.Ogura, K.Kohashi, R.Souzaki, Y.Kinoshita, T.Taguchi, MS.Hossain, M.Ohira, Y.Nakamura, A.Nakagawara:Neuronal leucine-rich repeat 1 negatively regulates anaplastic lymphoma kinase in neuroblastoma. Sci. Rep. 8;6:32682, 2016(原著)

5.  A.Sheikh, A.Takatori, MS.Hossain, MK.Hasan, M.Tagawa, H.Nagase, A.Nakagawara: Unfavorable neuroblastoma prognostic factor NLRR2 inhibits cell differentiation by transcriptional induction through JNK pathway. Cancer Sci., 107(9):1223-32, 2016(原著)

6. M.Fukuda, A.Takatori, Y.Nakamura, A.Suganami, T.Hoshino, Y.Tamura, A.Nakagawara: Effects of novel small compounds targeting TrkB on neuronal cell survival and depression-like behavior. Neurochem. Int., 97:42-48, 2016(原著)

7.  Y.Hasegawa, T.Iuchi, T.Sakaida, S.Yokoi, K.Kawasaki: The influence of carmustine wafer implantation on tumor bed cysts and peritumoral brain edema. J Clin Neurosci. 31:67-71, 2016.(原著)

8.  M.Saito, K.Okumura, Y.Yoshizawa, H.Munakata, E.Isogai, Y.Wakabayashi: Meis1 is required for c-Met inhibition to suppress cell proliferation of skin squamous cell carcinoma cells. J Biosci Med. 4 (1) : 53-65, 2016(原著)

9.  K.Kawamura, A.Wada, J-Y.Wang, Q.Li, A.Ishii, H.Tsujimura, T.Takagi, M.Itami, Y.Tada, K.Tatsumi, H.Shimada, K.Hiroshima, M.Tagawa:Expression of activation-induced cytidine deaminase is associated with a poor prognosis of diffuse large B cell lymphoma patients treated with CHOP-based chemotherapy. J Cancer Res Clin Oncol. 142: 27-36, 2016.(原著)(16-37)

10.  Y.Jiang, B.Zhong, K.Kawamura, T.Morinaga, M.Shingyoji, I.Sekine, Y.Tada, K.Tatsumi, H.Shimada, K Hiroshima, M.Tagawa:Combination of a third generation bisphosphonate and replication-competent adenoviruses augments the cytotoxicity on mesothelioma. BMC Cancer 16: 455, 2016.(原著)

11.  M. Nakamura, H. Sugimoto, T. Ogata, K. Hiraoka, H. Yoda, M. Sang, M. Sang, Y. Zhu, M. Yu, O. Shimozato, T. Ozaki: Improvement of gemcitabine sensitivity of p53-mutated pancreatic cancer MiaPaCa-2 cells by RUNX2 depletion-mediated augmentation of TAp73-dependent cell death. Oncogenesis, 5: e233, 2016. (原著)

12.  MS.Islam, Y.Tatsumi, R.Takano, T.Yokochi, J.Akter, T.Ozaki, Y.Nakamura, M.Ohira, A.Nakagawara: Transcriptional regulation of BMCC1 mediated by E2F1 in neuroblastoma cells. Biochem. Biophys. Res. Commu., 478: 81-86, 2016, (原著)

13. T.Ozaki, M.Nakamura, T.Ogata T, M.Sang, H.Yoda, K.Hiraoka, M.Sang, O.Shimozato: Depletion of pro-oncogenic RUNX2 enhances gemcitabine (GEM) sensitivity of p53-mutated pancreatic cancer Panc-1 cells through the induction of pro-apoptotic TAp63.Oncotarget, 7: 71937-71950, 2016. (原著)

14. 永瀬浩喜:がんのエピジェネティクス研究の進歩.臨床免疫・アレルギー科 65(4)345-350,2016.4(総説)

15.  田川雅敏:悪性中皮腫に対する遺伝子治療の現状.遺伝子医学MOOK30 P223-228メヂィカルドゥ 2016年6月20日(総説)

16.  Y.Maru, K.Orihashi, Y.Hippo: Lentivirus-Based Stable Gene Delivery into Intestinal Organoids. Methods Mol Biol 1422:13-21, 2016(原著)

17.  H.Nanri, Y.Nishida, K.Nakamura, K.Tanaka, M.Naito, G.Yin, N.Hamajima, N.Takashima, S.Suzuki, Y.Nindita, M.Kohno, H.Uemura, T.Koyama, S.Hosono, H.Mikami, M.Kubo, H.Tanaka: Associations between Dietary Patterns, ADRβ2 Gln27Glu and ADRβ3 Trp64Arg with Regard to Serum Triglyceride Levels: J-MICC Study. Nutrients. 8(9). pii: E545. doi: 10.3390/nu8090545. PMID: 27608039. 2016.(原著)

18.  Y.Nishida, M.Hara, T.Sakamoto, K.Shinchi, S.Kawai, M.Naito, N.Hamajima, A.Kadota, S.Suzuki, R.Ibusuki, A.Hirata, M.Yamaguchi, N.Kuriyama, I.Oze, H.Mikami, M.Kubo, H.Tanaka; Japan Multi-Institutional Collaborative Cohort (J-MICC) Study Group: Influence of cigarette smoking and inflammatory gene polymorphisms on glycated hemoglobin in the Japanese general population. Prev Med Rep. 3:288-295. doi:10.1016/j.pmedr.2016.03.010. 2016.(原著)

19. G.Yin, M.Naito, K.Wakai, E.Morita, S.Kawai, N.Hamajima, S.Suzuki, Y.Kita, T.Takezaki, K.Tanaka, M.Morita, H.Uemura, E.Ozaki, D.Hosono, H.Mikami, M.Kubo, H.Tanaka; Japan Multi-institutional Collaborative Cohort (J-MICC) Study Group: ALDH2 polymorphism is associated with fasting blood glucose through alcohol consumption in Japanese men. Nagoya J Med Sci. 78(2):183-193. 2016.(原著)

20. T.Nanami, H.Shimada, S.Yajima, Y.Oshima, K.Matsushita, F.Nomura, M.Nagata, M.Tagawa, S.Otsuka, A.Kuwajima, H.Kaneko: Clinical significance of serum autoantibodies against Ras-like GTPases, RalA, in patients with esophageal squamous cell carcinoma. Esophagus 13; 167-172, 2016.(原著)

21.  K.Hiroshima, D.Wu, M.Hasagawa, E.Koh, Y.Sekine, D.Ozaki, T.Yusa, A.E.Walts, A.M.Marchevsky, K.Nabeshima, Y.Tada, H.Shimada, M.Tagawa: Cytologic differential diagnosis of malignant mesothelioma and reactive mesothelial cells with FISH analysis of p16. Diagn Cytopathol. 44: 591-598, 2016.(原著)

22. K.Hasegawa, M.Tagawa, K.Takagi, H.Tsukamoto, Y.Tomioka, T.Suzuki, Y.Nishioka, T.Ohrui, M.Numasaki: Anti-tumor immunity elicited by direct intratumoral administration of a recombinant adenovirus expressing either IL-28A/IFN-λ2 or IL-29/IFN-λ1. Cancer Gene Ther. 23: 266-277, 2016.(原著)

23. X.Fan,Y.Li, C.Zhang, M.Sang, J.Cai, Q.Li, T.Ozaki, T.Ono, D.He: High mutation levels are compatible with normal embryonic development in Mlh1-deficient mice. Radiat. Res., 186: 377-384, 2016.(原著)

24.  S.Obinata, K.Takayama, K.Fujiwara, T.Suzuki, S.Tsutsumi, N.Fukuda, H.Nagase, T.Fujimura, T.Urano, Y.Homma, H.Aburatani, S.Takahashi S,Inoue: Targeting Oct1 genomic function inhibits androgen receptor signaling and castration-resistant prostate cancer growth. Oncogene 35(49):6350-6358, 2016(原著)

25.  H.Kano, T.Takayama, Y.Midorikawa, H.Nagase: Promoter hypomethylation of RAR-related orphan receptor α1 is correlated with unfavorable clinicopathological features in patients with colorectal cancer. BioScience Trends 10(3):202-209, 2016(原著)

26. 若尾文彦、西本寛、片野田耕太、祖父江友孝、三上春夫:がんの統計 '16 CANCER STATISTICS IN JAPAN-2016 がんの統計 '16, 2016年3月発行その他

27.  Y.Maru, N.Tanaka, M.Ohira, M.Itami, Y.Hippo, H.Nagase: Identification of novel mutations in Japanise ovarian clear cell carcinoma patients using optimized targeted NGS for clinical diagnosis. Gynectol Oncol 144(2):377-383, 2017(原著)

28.  T.Morinaga, S.Yanase, A.Okamoto, N.Yamaguchi, N.Yamaguchi: Recruitment of Lyn from endomembranes to the plasma membrane through calcium-dependent cell-cell interactions upon polarization of inducible Lyn-expressing MDCK cells. Sci Rep. 7(1): 493, 2017(原著)

29.  I.Hoshino, M.Nagata, N.Takiguchi, Y.Nabeya, A.Ikeda, S.Yokoi, A.Kuwajima, M.Tagawa, K.Matsushita, S.Yajima, H.Shimada: A panel of autoantibodies against multiple tumor-associated antigens for detecting gastric cancer. Cancer Sci 108: 308-315, 2017(原著)

30.  T.Ozaki, M.Nakamura, T.Ogata, M.Sang, O.Shimozato: The functional interplay between pro-oncogenic RUNX2 and hypoxia-inducing factor-1α (HIF-1α) during hypoxia-mediated tumor progression.

 Book Series: Human Cell Research, 2017, in press.(総説)

31.  筆宝義隆:発がんの機構と前がん状態-臨床にも応用-実地医家に必要ながん学 Medical Practice . 34, 8-13. 2017(総説)

32.  D.Wu, K.Hiroshima, T.Yusa, D.Ozaki, E.Koh, Y.Sekine, S.Matsumoto, K.Nabeshima, A.Sato, T.Tsujimura, H.Yamakawa, Y.Tada, H.Shimada, M.Tagawa: Usefulness of p16/CDKN2A fluorescence in situ hybridization and BAP1 immunohistochemistry for the diagnosis of biphasic mesothelioma. Ann. Diagn. Pathol. 26: 31-37, 2017(原著)

33. G.Ak, Y.Tada, H.Shimada, S.Metintas, M.Ito, K.Hiroshima, M.Tagawa, M.Metintas: Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin. BMC Cancer 17: 212, 2017(原著)

34.  R.Hoshi, Y.Watanabe, Y.Ishizuka, T.Hirano, E.Nagasaki-Maeoka, S.Yoshizawa, S.Uekusa, H.Kawashima, K.Ohashi, K.Sugito, N.Fukuda, H.Nagase, M.Soma, T.Ozaki, T.Koshinaga, K.Fujiwara: Depletion of TFAP2E attenuates adriamycin-mediated apoptosis in human neuroblastoma cells. Oncology Rep.37: 2459-2464, 2017.(原著)

35.  Y.Kangawa, T.Yoshida, K.Maruyama, M.Okamoto, T.Kihara, M.Nakamura, M.Ochiai, Y.Hippo, SM.Hayashi, M.Shibutani: Cilostazol and enzymatically modified isoquercitrin attenuate experimental colitis and colon cancer in mice by inhibiting cell proliferation and inflammation. Food Chem Toxicol. 100:103-114. 2017 (原著)

 

 大規模な他施設共同試験の成果

千葉県がんセンターが参加している大規模臨床試験の成果は下記のURLでご覧いただけます。

JCOG(Japan Clinical Oncology Groop)

WJOG(West Japan Oncology Group)外部サイトへのリンク